BioSpace News Archive

Nuvalent, Inc. announced the presentation of new preclinical data for NVL-330, its recently nominated HER2-selective inhibitor, and NVL-655, its ALK-selective inhibitor currently under investigation in the ALKOVE-1 Phase 1/2 study for advanced ALK-positive non-small cell lung cancer and other solid tumors.

Arbutus Biopharma Corporation today announced that it has scheduled its third quarter 2022 financial results and corporate update for Wednesday, November 9, 2022.

Accuray Incorporated announced that the Japanese Ministry of Health, Labor and Welfare has approved reimbursement for the CyberKnife® System for the treatment of trigeminal neuralgia.

Asahi Kasei Bioprocess America, a subsidiary of diversified Japanese multinational company Asahi Kasei, is currently undergoing a dramatic expansion of their Glenview, Illinois facilities to fuel innovation and to meet growing market needs for fluid management equipment, virus filtration and hollow fiber membrane technology.

Medable Inc. , the industry-leading technology platform for patient-centered clinical trials, today announced a new patient-first oncology offering that enables life sciences companies to improve patient access, enrollment, and retention in cancer trials.

Massive Bio , a leader in AI-powered cancer clinical trial enrollment, today announced that the company exceeded its goal to onboard 100,000 cancer patients in its platform by the end of 2022 – nine months sooner than expected.

HTG Molecular Diagnostics, Inc. and OmiCure® announced a collaboration with OmiCure to implement the HTG Transcriptome Panel as an alternative to RNA-Seq to inform the OmiCure test and help guide therapeutic decision-making across several cancer types.

Fortive Corporation (“Fortive”) (NYSE: FTV) today announced financial results for the third quarter 2022.

X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, announced the appointment of Mark Baldry to the position of Chief Commercial Officer.

Sema4, a health insights company, has collaborated on research debunking a commonly held belief that exome and genome sequencing deliver more inconclusive results than multi-gene panels.